INSILICO Aktie

 

According to Bloomberg, citing sources, INSILICO (03696.HK) is considering a secondary listing in Abu Dhabi, potentially becoming the first non-Gulf company to list on the local exchange.INSILICO, which only went public in Hong Kong last December, has reportedly begun preliminary discussions about listing on the Abu Dhabi Securi......

Hong Kong-listed biotech firm Insilico Medicine Cayman TopCo is considering a secondary listing in Abu Dhabi, people familiar with the matter said, in a deal that would make it the first company from outside the Gulf to list shares on a regional exchange....

Insilico Medicine Founder & CEO Alex Zhavoronkov discusses how his company aims to apply artificial intelligence to revolutionize drug discovery and longevity research. He speaks with Haslinda Amin from the sidelines of 'JPMorgan Global China Summit' in Shanghai. (Source: Bloomberg)...

UBS published a report initiating coverage on INSILICO (03696.HK) with a Buy rating and a target price of HKD77, equivalent to a forecast 2026 price-to-sales ratio of 31.3x, in line with global peers. The broker noted that INSILICO is a global leader in AI-driven drug discovery (AIDD), leveraging its end-to-end proprietary Pharm......

SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in......

SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. ("Ribo",......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE. The inhalation solution is designed for targeted lung......

INSILICO (03696.HK) announced that its clinical trial application for the self-developed Rentosertib (ISM001-055) inhalation formulation for the treatment of adult idiopathic pulmonary fibrosis (IPF) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China. This marks the......

For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi......

Insilico Medicine (03696.HK) announced that it has officially nominated ISM0387, an MTA-cooperative PRMT5 inhibitor, as a preclinical candidate (PCC).The molecule was discovered in the United Arab Emirates by Insilico Medicine's UAE team using the company's proprietary Pharma.AI platform. The early-stage drug discovery process, ......

CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board). The initiative provides......

Insilico Medicine (03696.HK) has made new progress in its unified AI framework for drug target discovery. The companys share price opened up 0.08% today (20th) and extended gains, reaching an intraday peak of HKD71.4. It is currently trading at HKD71.3, up 17.27%, with turnover of 6.2793 million shares, involving HKD426 million......

Die SZ bezeichnete ihn bereits als "Elon Musk der Pharmaindustrie": Alex Zhavoronkov. Der gebürtige Lette will mit Insilico Medicine, die seit Ende vergangenen Jahres börsennotiert ist, mithilfe von Künstlicher Intelligenz (KI) die Forschung und Entwicklung von Wirkstoffen völlig neu definieren....

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space....

Eli Lilly investiert Milliarden in künstliche Intelligenz, um die nächste Generation von Medikamenten zu entwickeln. Die Kooperation mit Insilico könnte Forschung radikal beschleunigen – und den Wettbewerb neu ordnen....

Eli Lilly baut seine KI-Strategie massiv aus. Ein milliardenschwerer Deal zeigt, wie stark künstliche Intelligenz die Arzneimittelentwicklung verändern könnte....

Der Pharma-Riese Eli Lilly baut seine KI-gestützte Wirkstoffforschung aus. Wie am Wochenende bereits zuvor die Financial Times (FT) berichtete, schnüren die Amerikaner einen milliardenschweren Deal mit der in Hongkong gelisteten Insilico Medicine....